Compare Boston Beer Company Inc (SAM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Summit Therapeutics Inc — how do they compare? Boston Beer Company Inc trades at $183.69 (market cap $1.86B), while Summit Therapeutics Inc trades at $15.02 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 6.5× Boston Beer Company Inc's market cap. Which is the better fit depends on your goals.
| SAM | SMMT | |
|---|---|---|
Market Cap | $1.86B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $26.98 |
52-Week Low | $161.08 | $12.55 |
Enterprise Value | $1.63B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAM trades at $182.97, up 1.09% on the day, with a bearish technical signal and mixed earnings performance. Recent quarters show misses against estimates, though Q4 2025 beat expectations. The company maintains positive operating cash flow but faces revenue declines and a negative net income margin for 2026. Analyst sentiment is cautious, with a consensus price target of $207.33, while institutional selling and weak demand headlines add pressure.
Outlook is guarded due to volume declines and competitive pressures, offset by a debt-free balance sheet and margin improvements. Risks include sustained demand weakness and execution challenges, but valuation metrics like P/S of 0.99 may attract value investors if turnaround efforts gain traction.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
